Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus

Transplantation

Volumn 91, Issue 1, 2011, Pages 78-85

  Miura, Yoshiko ^a   Satoh, Shigeru ^a   Saito, Mitsuru ^a   Numakura, Kazuyuki ^a   Inoue, Takamitsu ^a   Obara, Takashi ^a   Tsuruta, Hiroshi ^a   Narita, Shintaro ^a   Horikawa, Yohei ^a   Tsuchiya, Norihiko ^a   Komatsuda, Atsushi ^a   Kagaya, Hideaki ^b   Miura, Masatomo ^b   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Automated image analysis; Chronic allograft injury; CYP3A5 polymorphism; Interstitial fibrosis; Time zero biopsy

Indexed keywords

BASILIXIMAB; CYTOCHROME P450; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMAGING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK FACTOR;

ADULT; AGED; BODY MASS INDEX; CHRONIC DISEASE; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78751641894     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ff4f7f     Document Type: Article

References (40)

1. Servais A, Meas-Yedid V, Buchler M, et al. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation 2007;84:1595.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Eng J Med 2003;349:2326.
3. Pape L, Henne T, Offner G, et al. Computer-assisted quantification of fibrosis in chronic allograft nephropathy by picrosirius red-staining: A new tool for predicting long-term graft function. Transplantation 2003;76:955.
4. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518.
5. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008;8:753.
6. Diaz Encarnacion MM, Griffin MD, Slezak JM, et al. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2004;4:248.
7. Grimm PC, Nickerson P, Gough J, et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003;14:1662.
8. Mancilla E, Avila-Casado C, Uribe-Uribe N, et al. Time-zero renal biopsy in living kidney transplantation: A valuable opportunity to correlate predonation clinical data with histological abnormalities. Transplantation 2008;86:1684.
9. Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004;19(suppl 3): iii11.
10. Scolari MP, Cappuccilli ML, Lanci N, et al. Predictive factors in chronic allograft nephropathy. Transplant Proc 2005;37:2482.
11. Nankivell BJ, Borrows RJ, Fung CL, et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004;78:434.
12. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010;10:563.
13. Reisching T, Jindra P, Hes O, et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009;87:436.
14. Heilman RL, Chakkera HA, Reddy KS, et al. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant 2008;22:309.
15. Micozkadioglu H, Ozdemir FN, Sezer S, et al. Weight gain after livingrelated renal transplantation affects long-term graft function. Transplant Proc 2005;37:1029.
16. Arias M, Fernández-Fresnedo G, Rodrigo E, et al. Non-immunologic intervention in chronic allograft nephropathy. Kidney Int Suppl 2005: S118.
17. Ortiz F, Paavonen T, Tornroth T, et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol 2005;16:817.
18. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of intersititial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009;88:897.
19. Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003;64:1027.
20. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:1182.
21. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245.
22. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383.
23. Servais A, Meas-Yedid V, Toupance O, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009;9:2552.
24. Moreso F, Lopez M, Vallejos A, et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001;1:82.
25. Seron D, Moreso F. Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. Kidney Int 2007;72:690.
26. Nakorchevsky A, Hewel JA, Kurian SM, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010;21:362.
27. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121.
28. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711.
29. *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 2009;65:473.
30. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1.
31. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med 2007;357:2562.
32. Strutz F. Pathogenesis of tubularinterstitial fibrosis in chronic allograft dysfunction. Clin Transplant 2009;23(suppl 21):26.
33. Shiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374.
34. Japanese study of kidney transplantation: 1. Results of early phase II study. Transpl Int 1992;5(suppl 1): S524.
35. Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006;17:881.
36. Brandhorst G, Brehmer F, Petrova DT, et al. Mycophenolic acid presode concentrations and renal function in a mouse model for progressive renal fibrosis. Ther Drug Monit 2010;32:73.
37. Djamali A, Vidyasagar A, Yagci G, et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-β1-induced activation of nox-2 through the nuclear factor-κB pathway. Transplantation 2010;90:387.
38. Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005;80:1419.
39. Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: Occurrence of acute rejection. J Clin Pharmacol 2003;43:859.
40. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982.